Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer a phase II randomised study

Next Previous
Trial Profile

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer a phase II randomised study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Chemotherapy-induced damage
  • Focus Adverse reactions
  • Acronyms OXTOX

Most Recent Events

  • 18 Dec 2026 According to a MediciNova edia release, this is an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, in which 100 patients have been randomized across two treatment arms at 11 clinical sites in Australia. The study will conclude when the final patient reaches six months post-chemotherapy. Topline data may be available later in 2026.
  • 18 Dec 2025 According to a MediciNova edia release, status changed from recruiting to active, no longer recruiting.
  • 16 Apr 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top